CCCC

C4 Therapeutics, Inc.

• Dow Jones·03/25 17:11

  C4 Therapeutics' Shares Rise on First Dosing in Multiple Myeloma Trial

• TipRanks·03/25 11:25

  C4 Therapeutics doses first patient in cemsidomide trial

• Benzinga·03/25 11:09

  C4 Therapeutics Starts Trial For New Multiple Myeloma Drug Combo

• Reuters·03/25 11:01

  C4 Therapeutics doses first patient in Phase 1b cemsidomide-elranatamab trial for relapsed/refractory multiple myeloma; enrollment grows to 54 patients

• Reuters·03/25 11:00

  C4 THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B TRIAL OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB (ELREXFIO®) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

• Seeking Alpha·03/10 11:49

  C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

• Reuters·03/09 20:01

  C4 Therapeutics grants 85,480 inducement stock options to new employee

• Reuters·03/09 20:01

  C4 THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

• Reuters·03/03 12:04

  C4 Therapeutics Publishes Corporate Presentation on Targeted Protein Degradation Pipeline in Oncology and INN Diseases

• Simply Wall St·02/28 01:25

  C4 Therapeutics (CCCC) Quarterly Loss Narrows To US$20.5m Challenging Persistent Bearish Narratives

• Dow Jones·02/27 15:18

  C4 Therapeutics Is Maintained at Overweight by Barclays

• Benzinga·02/27 15:08

  Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

• TipRanks·02/27 12:40

  Guggenheim Keeps Their Buy Rating on C4 Therapeutics (CCCC)

• TipRanks·02/27 10:25

  C4 Therapeutics price target raised to $7 from $5 at Barclays

• TipRanks·02/27 07:45

  C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating